Sharemaestro company-news research for Jiangsu Hengrui Pharmaceuticals Co.,Ltd (1276), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

HKG Hong Kong Provisional evidence

Company news sentiment

Latest 1276 news and sentiment

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report RSS feed
30-day score51Neutral is 50
Early balanced news score 17/100 evidence confidence 100% direct company focus 9 current stories across 2 publishers
Latest weekly closeHKD 47.94week of 28 Aug 2026
Main news subjectEarnings70/100 share of current news
News data statusPartial1 duplicate stories removed

Current company news

Early balanced news score

9 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone65/100 Published 30-day score51/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline Jiangsu Hengrui Pharmaceuticals Co. ADRs, each representing 2 ordinary shares (JHPCY.US), will release their financial report after the market close on August 19. Moomoo · 20 Aug 2026 21:20

What supports the score

Direct evidence

9 current stories are mapped specifically to 1276.

What limits the score

Source breadth

Only 2 publishers currently contribute to the measured read.

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.040.

Confidence

Confidence is 17/100, below the threshold for a firm score.

51/100
News scoreEarly balanced news score
17/100
Confidencethin evidence
100%/100
Company news9 company stories
100/100
Story agreement0/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
19 Aug: 4 stories20 Aug: 3 stories 19 Aug: tone 61, 4 stories20 Aug: tone 50, 3 stories 95505
07 Aug22 Aug05 Sep
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence1
0.04 after freshness weighting
Source breadth40
2 independent publishers
Company relevance100
share tied directly to this company
Freshness5
recency-weighted evidence
Agreement100
how closely stories agree
Publisher mix50
less reliance on one publisher

Price and news history

Weekly price and news-score history

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

26 completed price weeks9 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
06 Mar 2026: close 65.122932, indexed 100.013 Mar 2026: close 63.777626, indexed 97.920 Mar 2026: close 64.525017, indexed 99.127 Mar 2026: close 65.770676, indexed 101.003 Apr 2026: close 66.418419, indexed 102.010 Apr 2026: close 67.265465, indexed 103.317 Apr 2026: close 66.169289, indexed 101.624 Apr 2026: close 68.610771, indexed 105.401 May 2026: close 65.0, indexed 99.808 May 2026: close 64.550003, indexed 99.115 May 2026: close 65.75, indexed 101.022 May 2026: close 61.349998, indexed 94.229 May 2026: close 60.200001, indexed 92.405 Jun 2026: close 54.5, indexed 83.712 Jun 2026: close 55.150002, indexed 84.719 Jun 2026: close 54.650002, indexed 83.926 Jun 2026: close 52.950001, indexed 81.303 Jul 2026: close 59.900002, indexed 92.010 Jul 2026: close 59.25, indexed 91.017 Jul 2026: close 55.049999, indexed 84.524 Jul 2026: close 56.650002, indexed 87.031 Jul 2026: close 57.099998, indexed 87.707 Aug 2026: close 58.5, indexed 89.814 Aug 2026: close 52.799999, indexed 81.121 Aug 2026: close 48.200001, indexed 74.028 Aug 2026: close 47.939999, indexed 73.6 03 Jul 2026: news score 51, close 59.900002, 2 stories5110 Jul 2026: news score 51, close 59.25, 3 stories17 Jul 2026: news score 54, close 55.049999, 4 stories5424 Jul 2026: news score 54, close 56.650002, 6 stories31 Jul 2026: news score 53, close 57.099998, 6 stories5307 Aug 2026: news score 51, close 58.5, 8 stories14 Aug 2026: news score 51, close 52.799999, 6 stories5121 Aug 2026: news score 53, close 48.200001, 11 stories28 Aug 2026: news score 51, close 47.939999, 9 stories51 Price index 109.2 89.5 69.8 News score 100 50 0
06 Mar02 Jun28 Aug
Weekly close, indexedSentiment score
26-week price-26.4%latest close 47.94
News score change+0first to latest comparable week
One-week response-0.5%Price digesting
Fair-value position-28.8%Below fair value
WeekNews scoreCloseWeekly move
28 Aug 202651HKD 47.939999-0.5%
21 Aug 202653HKD 48.200001-8.7%
14 Aug 202651HKD 52.799999-9.7%
07 Aug 202651HKD 58.5+2.5%
31 Jul 202653HKD 57.099998+0.8%
24 Jul 202654HKD 56.650002+2.9%
17 Jul 202654HKD 55.049999-7.1%
10 Jul 202651HKD 59.25-1.1%
Provisional evidence

News subjects

What is shaping the score

Earnings
Earnings523 stories · 33%
Market update503 stories · 33%
Capital return652 stories · 22%
Deals and strategy501 stories · 11%

Source mix

Where the evidence comes from

50/100 independence
TipRanks593 stories · 33%
The Globe and Mail502 stories · 22%
finance.biggo.com651 stories · 11%
finance.yahoo.com551 stories · 11%
Moomoo501 stories · 11%
South China Morning Post501 stories · 11%

Recurring subjects

Subjects appearing most often

Current evidence
Pharma1IPO1Financial Results1Fda Approval1Earnings1Clinical Trials1

Earlier readings

How the score has changed

13 comparable readings · 64 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+150 to 51 · Broadly stable
Observed range50–5650 is the neutral baseline
Evidence depth9stories at latest stored reading · +8
Confidence18/100Provisional · +18
28 Jun50 neutral01 Sep 10:23
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
01 Sep 10:2351-218/100 (-13)9 (-3)Provisional
20 Aug 23:5953-131/100 (-2)12 (+3)Provisional
19 Aug 23:5954+233/100 (+14)9 (+1)Provisional
06 Aug 23:5952+019/100 (-1)8 (+1)Provisional
05 Aug 23:5952-220/100 (-9)7 (0)Provisional
28 Jul 23:5954+129/100 (+1)7 (0)Provisional
27 Jul 23:5953-228/100 (-2)7 (+1)Provisional
22 Jul 23:5955+030/100 (0)6 (+1)Provisional

Source headlines

The news behind the score

Showing 1-9 of 9

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#1—Not directional
MoomooDirect company coverageScored from headline

Jiangsu Hengrui Pharmaceuticals Co. ADRs, each representing 2 ordinary shares (JHPCY.US), will release their financial report after the market close on August 19.

Published
20 Aug 2026 21:20
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 14.1d old
Duplicates
1 consolidated
#2—Not directional
The Globe and MailDirect company coverageScored from headline

Jiangsu Hengrui Pharmaceuticals Announces Resignation of Joint Company Secretary

Published
20 Aug 2026 14:29
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 14.4d old
Duplicates
1 consolidated
#3—Not directional
The Globe and MailDirect company coverageScored from headline

Jiangsu Hengrui Proposes 2026 H Share Incentive Scheme to Strengthen Governance

Published
20 Aug 2026 14:28
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 14.4d old
Duplicates
1 consolidated
#6—Not directional
TipRanksDirect company coverageScored from headline

Jiangsu Hengrui Publishes Unaudited Interim Results for First Half of 2026

Published
19 Aug 2026 13:42
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 15.5d old
Duplicates
1 consolidated
#7—Not directional
finance.yahoo.comDirect company coverageStored article

Hengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business Momentum

SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first half of 2026. During the reporting period, innovative drugs remained the Company's key growth driver, while globalization initiatives continued to validate the global value of Hengrui's innovation portfolio. Financial Highlights In the first half of 2026, Hengrui reported revenue of RMB15.46 billion. Drug sales revenue was RMB13.95 billion, representing a year-over-year increase of 1.87%. Innovative drug sales increased by 16.38% year-over-year and accounted f

Clinical TrialsEarningsFda ApprovalFinancial ResultsIPOPharma
Published
19 Aug 2026 11:46
News subject
Earnings
Why this score
Operating growth
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 15.5d old
Duplicates
1 consolidated
#8—Not directional
TipRanksDirect company coverageScored from headline

Jiangsu Hengrui Board to Review Interim Results and Dividend in August

Published
06 Aug 2026 09:48
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 28.6d old
Duplicates
1 consolidated
#9—Not directional
South China Morning PostDirect company coverageScored from headlineSource lookup

China’s Hengrui gets boost from fifth drug-licensing deal of year

Published
05 Aug 2026 23:18
News subject
Deals and strategy
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 29.1d old
Duplicates
1 consolidated

Earlier company news

1276 news archive

8 older headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Older news is kept in the archive

There are 8 older 1276 headlines. Open one page at a time when you need them.

Open older archive

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context